Elkfork Partners LLC acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 84,896 shares of the pharmaceutical company’s stock, valued at approximately $6,254,000.
Other large investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its stake in shares of Vertex Pharmaceuticals by 1.0% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,483,388 shares of the pharmaceutical company’s stock worth $2,047,986,000 after buying an additional 235,525 shares in the last quarter. Capital World Investors boosted its stake in shares of Vertex Pharmaceuticals by 2.8% in the third quarter. Capital World Investors now owns 22,292,383 shares of the pharmaceutical company’s stock worth $1,944,119,000 after buying an additional 599,586 shares in the last quarter. State Street Corp boosted its stake in shares of Vertex Pharmaceuticals by 2.7% in the fourth quarter. State Street Corp now owns 11,774,161 shares of the pharmaceutical company’s stock worth $867,393,000 after buying an additional 308,574 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Vertex Pharmaceuticals by 2.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 6,492,221 shares of the pharmaceutical company’s stock worth $566,187,000 after buying an additional 144,397 shares in the last quarter. Finally, BlackRock Fund Advisors boosted its stake in shares of Vertex Pharmaceuticals by 3.9% in the third quarter. BlackRock Fund Advisors now owns 6,262,876 shares of the pharmaceutical company’s stock worth $546,185,000 after buying an additional 234,950 shares in the last quarter. Hedge funds and other institutional investors own 94.85% of the company’s stock.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded up 1.36% during mid-day trading on Tuesday, reaching $88.91. 2,321,557 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $82.62 and a 200-day moving average price of $86.69. The stock’s market cap is $22.08 billion. Vertex Pharmaceuticals Incorporated has a 12 month low of $71.46 and a 12 month high of $103.73.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, January 25th. The pharmaceutical company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.06. The business had revenue of $458.71 million for the quarter, compared to the consensus estimate of $453.40 million. Vertex Pharmaceuticals had a negative net margin of 6.76% and a negative return on equity of 2.15%. During the same period last year, the firm posted $0.17 earnings per share. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post $1.67 earnings per share for the current fiscal year.
“Elkfork Partners LLC Acquires Shares of 84,896 Vertex Pharmaceuticals Incorporated (VRTX)” was first reported by sleekmoney and is owned by of sleekmoney. If you are viewing this article on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this article can be accessed at http://sleekmoney.com/elkfork-partners-llc-acquires-shares-of-84896-vertex-pharmaceuticals-incorporated-vrtx/1660926.html.
A number of equities research analysts recently issued reports on VRTX shares. BMO Capital Markets reiterated a “market perform” rating and issued a $88.00 price objective on shares of Vertex Pharmaceuticals in a report on Wednesday, November 30th. Oppenheimer Holdings, Inc. started coverage on shares of Vertex Pharmaceuticals in a report on Thursday, December 15th. They issued a “market perform” rating for the company. Vetr upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $90.91 price objective for the company in a report on Thursday, January 19th. Barclays PLC cut shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $100.00 to $90.00 in a report on Tuesday, November 29th. Finally, JMP Securities cut shares of Vertex Pharmaceuticals to a “market perform” rating in a report on Monday, January 9th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Vertex Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $100.94.
In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 8,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, January 11th. The shares were sold at an average price of $82.48, for a total transaction of $659,840.00. Following the transaction, the director now directly owns 276,225 shares of the company’s stock, valued at $22,783,038. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Joshua S. Boger sold 6,500 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $91.55, for a total transaction of $595,075.00. Following the transaction, the director now directly owns 274,725 shares in the company, valued at $25,151,073.75. The disclosure for this sale can be found here. Insiders sold 53,500 shares of company stock worth $4,330,000 over the last ninety days. 1.90% of the stock is currently owned by insiders.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/elkfork-partners-llc-acquires-shares-of-84896-vertex-pharmaceuticals-incorporated-vrtx/1660926.html
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.